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Oxidative consumption of nitric oxide: A potential mediator as anemia and hypertension; however, it was the work
of uremic vascular disease. Recent data has drawn our attention of London et al [3] that also demonstrated a link between
to the relationship between altered biomechanical properties LVH and changes in the vasculature in end-stage renalof the vasculature and left ventricular hypertrophy (LVH) in
disease (ESRD). Their pivotal studies demonstrated thaturemia. We have been able to show that uremia causes func-
uremic patients have increased intima-media thicknesstional changes in the conduit vessels of rats, predating structural
changes and independent of blood pressure. As nitric oxide and reduced compliance of conduit vessels, resulting in
(NO) is a potent modulator of the cardiovascular system, we early return of arterial wave reflections. This in turn
studied the NO pathway in uremia. The existing data are some-
increases the pulsatile pressure load on the heart, con-what confusing, with some suggesting up-regulation of the NO
tributing to LVH in dialysis patients.system, and others the opposite. When examined critically,
however, a pattern emerges, with studies examining NO release
showing increased production, whereas those examining NO
DO FUNCTIONAL ALTERATIONS PRECEDEbioactivity show it to be attenuated. We hypothesized that there
is increased NO release, but excess consumption in uremia. Our STRUCTURAL CHANGES?
own data on NO metabolites (NOx) in the serum of healthy
Savage et al [4] in our laboratory examined the myo-young male hemodialysis patients indicate higher concentra-
genic tone of femoral vessels harvested from Wistar Ky-tions both pre- and post-dialysis compared to controls. As the
endothelium is a potential source of NO, we cultured endothe- oto rats rendered uremic by a two-stage, 5/6 nephrec-
lial cells in uremic plasma. These studies demonstrated in- tomy procedure. These animals were only mildly uremic
creased basal NO release from cells cultured under uremic and still normotensive. Femoral vessels harvested fromconditions compared to controls. Furthermore, alterations in
these animals were mounted on a pressure myographarginine metabolism appear to play a role, as there is evidence
and the myogenic tone studied. The uremic vessels hadfor reduced arginase activity in these cells, thereby increasing
arginine availability for the NO pathway. Given the in vivo data higher myogenic tone compared to sham-operated con-
and clinical characteristics of the uremic syndrome suggesting trols (Fig. 1). Furthermore, the myogenic tone correlated
reduced NO bioactivity, we examined the possibility that the
directly with the degree of uremia. Interestingly, becauseexcess NO generated is being consumed and rendered bio-
of the mild degree of uremia, these vessels did not dem-inactive. Aortae from uremic and control rats were stained
for the presence of nitrotyrosine. All uremic aortae stained onstrate any histologic differences compared to controls,
positively, but nitrotyrosine was not present in any control indicating that functional changes precede structural
aortae. ones. Further studies were then carried out using the
same model but with rats receiving a nonhypotensive
dose of ramipril. When the myogenic tone of the femoral
The association between cardiovascular pathology and vessels was studied, there were no differences between
uremia has its origins in the original description of
controls and uremics [5].
Bright’s disease from 1836. Richard Bright, in his post-
Ramipril and the other ACE inhibitors not only inhibitmortem studies of patients with ‘albuminous’ urine,
the formation of angiotensin 2, but also inhibit the break-noted a high prevalence of left ventricular hypertrophy
down of bradykinin. Bradykinin is vasoactive, being a(LVH) [1]. Despite the advances in medicine in the in-
powerful agonist of endothelial nitric oxide synthasetervening years, 84% of patients starting dialysis still
(eNOS). Ibels [6] previously described intimal thickeninghave abnormal echocardiograms, with LVH predomi-
and medial calcification in uremic vessels, changes thatnating [2]. This was originally attributed to factors such
closely resemble the neointima formation seen in the
balloon injury model. In this form of injury, the role of
Key words: oxidative stress, nitric oxide, uremia, vascular disease. nitric oxide (NO) is well established, with numerous
studies in which increased local NO production attenu- 2003 by the International Society of Nephrology
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Fig. 1. Myogenic tone in uremic and control rats at 100 mm Hg. Intra-
vascular pressure shows increased tone in the uremic vessels.
ated neointima formation [7]. It is possible, therefore,
that the mechanism underlying the beneficial role of
ramipril in the above study was restoration of NO and, Fig. 2. NOx concentrations in the plasma of hemodialysis patients pre-
dialysis (preD), and the same patients immediately postdialysis (postD)hence, abnormalities of NO may underlie the changes
compared with the control. NOx was measured using the Greiss reac-in the vasculature in uremia. tion.
WHOLE BODY NO PRODUCTION IN UREMIA
Various studies have attempted to address this ques-
tion. When interpreting the literature, it is important
to differentiate between studies that examine basal NO
release as opposed to those that study stimulated NO
production. We feel that basal NO tone is more relevant
in the pathogenesis of the chronic vascular changes seen
in uremia. Experiments which measure the urinary ex-
cretion of products of NO metabolism (nitrates and ni-
trites [Nox]) usually suggest reduced NO tone in patients
with chronic renal failure [8]. This method has its prob-
lems in that NOx excretion is affected by GFR and, Fig. 3. Concentration of NOx in supernatants of cells previously cul-
tured in 10% uremic or control human plasma (A), and concentrationsfurthermore, this technique does not differentiate local
of intracellular arginine and ornithine in cells previously cultured in
and systemic production of NO. The blood pressure of 10% human uremic or control serum (B).
subjects with uremia in these studies also was either
not measured or elevated. However, when studies have
measured assessed plasma NO by circulating NOx or
as it is a contributor to basal NO tone. We culturedcGMP, NO production has shown to be increased [9].
human microvascular endothelial cells (HMEC) in 10%Our own unpublished data supports this, with levels of
human uremic or control plasma for 48 hours to studyNOx higher than controls both pre- and post-hemodialy-
the acute effects of uremia on NO production. Cellssis (Fig. 2). Other studies on basal NO production in
were then washed and incubated with medium devoiddifferent models of uremia have also shown increased
of plasma for 30 minutes, after which supernatants wereNO production [10]. When more detailed studies on NO
collected for NOx measurements using a chemilumines-metabolism using nonradioactive isotopes of arginine
cence assay. The cells previously cultured in uremicand citrulline have been employed, total NO production
plasma produced increased quantities of NO comparedhas shown to be increased [11].
to those cultured in control plasma (Fig. 3A). This data is
in keeping with that of Remuzzi et al [12]. The underlying
NO PRODUCTION FROM mechanism for this finding was further explored. Reverse
UREMIC ENDOTHELIUM transcription PCR was used to study expression of induc-
ible nitric oxide synthase (iNOS) and eNOS using theThe above studies fail to identify the source of the
increased NO. We chose to examine the endothelium, above cell culture protocol. No iNOS mRNA was found
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in either the control or uremic group. eNOS mRNA was We have shown that pathophysiologic concentrations of
homocysteine (putative uremic vascular toxin) causedpresent in both, but in equal quantities.
We then studied arginine metabolism in these cells, impaired endothelial NO-dependent relaxation. This
phenomenon could be due to binding of NO to homocys-using the same experimental protocol. Data from the
1950s [13] and 1970s [14] suggest that arginase activity teine, as suggested by Stamler et al [20]; however, the ob-
served effect was completely reversed by the superoxideis reduced in uremic erythrocytes, leukocytes, and hepa-
tocytes. If arginase were inhibited, one would expect dismutase mimetic TEMPOL (stable nitroxide 4-hydroxy
tempo). Subsequent removal of Tempol resulted in reap-more arginine to be available for the NO pathway. We
tested this hypothesis by measuring ornithine in the cells pearance of endothelial dysfunction [abstract; Hacks D,
Nephrol Dial Transplant 17(1):30, 2002]. This suggestedand supernatants. We found reduced concentrations of
ornithine in both supernatants and cells of the uremic that superoxide generating systems are up-regulated by
pre-incubation with homocysteine; however, the mecha-group (Fig. 3B). In addition, we also found increased
intracellular concentrations of arginine in the cells pre- nisms underlying this remain elusive.
viously cultured in uremic plasma (Fig. 3B). This could
be explained by increased arginine transport, as was pre-
CONCLUSIONSviously described [15], or by increased recycling via the
Together, there appears to be a compelling argumentcitrulline-arginine salvage pathway [16]. These cell cul-
for increased basal production of NO in uremia. Theture studies allow us to speculate about events occurring
NO release, however, is largely consumed when it reactsin vivo but do not account for the altered biomechanical
with superoxide, resulting in the formation of peroxyni-and histologic changes that are observed in patients with
trite. The resultant vascular damage predates structuralESRD.
changes that will follow later and contribute to the LVH
that is so much a feature of uremia.
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